Myo-inositol does appear to increase progesterone levels, particularly in women with polycystic ovary syndrome (PCOS). In a 12-week randomized controlled study, women taking myo-inositol had significantly higher mid-luteal progesterone compared to those taking only folic acid. The effect isn’t a direct hormonal boost, though. Inositol works by improving ovarian function and helping the body ovulate properly, which is the natural trigger for progesterone production.
How Inositol Raises Progesterone
Progesterone is produced by the corpus luteum, a temporary structure that forms in the ovary after an egg is released. No ovulation means no corpus luteum, which means very little progesterone. This is the core problem for many women with PCOS: irregular or absent ovulation leads to chronically low progesterone.
Myo-inositol addresses this at multiple levels. Inside the ovary, it enhances the activity of FSH (the hormone that stimulates follicle growth) and increases aromatase, an enzyme that converts androgens into estrogens. This shift from androgen-dominant to estrogen-dominant signaling is critical for a follicle to mature fully and release an egg. Once estrogen rises sufficiently, it triggers an increase in progesterone receptors, and the subsequent ovulation kicks off progesterone production. In a landmark study published in the New England Journal of Medicine, 19 out of 22 women with PCOS who took inositol ovulated, compared to just 6 out of 22 on placebo.
So inositol doesn’t manufacture progesterone directly. It restores the conditions that allow your body to produce it on its own.
The Insulin Connection
A major reason ovulation fails in PCOS is insulin resistance. Around 70% to 80% of women with PCOS and central obesity have insulin resistance, and even 15% to 30% of lean women with PCOS are affected. When insulin levels stay high, the signal amplifies androgen production in the ovaries through increased LH secretion. Excess androgens block normal follicle development, preventing ovulation and, by extension, progesterone production.
Myo-inositol acts as an insulin-sensitizing agent. In a 12-week trial of 50 overweight women with PCOS, 2 grams of myo-inositol daily led to significant reductions in insulin levels, testosterone, LH, and the LH-to-FSH ratio. Lower insulin means less androgen stimulation, which gives follicles a better chance to mature. A review of 12 studies confirmed that myo-inositol improves hormonal balance, oocyte maturation, and pregnancy rates in women with PCOS.
What the Progesterone Numbers Look Like
A prospective randomized study measured mid-luteal (day 21) progesterone in women with PCOS after 12 weeks of myo-inositol supplementation. The myo-inositol group averaged a progesterone level of 5.22, compared to 4.77 in the control group. While that difference may look modest, it was statistically significant, and the researchers noted it as a reliable marker that ovulation had occurred. For women who previously weren’t ovulating at all, even a moderate rise in luteal progesterone represents a meaningful shift toward normal cycles and fertility.
Myo-Inositol vs. D-Chiro-Inositol
These two forms of inositol behave quite differently in the ovary. Myo-inositol supports estrogen production and FSH signaling, nudging the hormonal environment toward ovulation. D-chiro-inositol (DCI), on the other hand, favors androgen production and actually suppresses aromatase, the enzyme myo-inositol activates. In PCOS, the ratio of DCI to myo-inositol in the ovaries is already too high, which is part of the problem.
This doesn’t mean DCI is harmful in all contexts. At a dose of 1,200 mg per day, DCI reduced insulin levels by 62% and free testosterone by 55% in obese women with PCOS over eight weeks. It also restored ovulation in a well-known trial. But taking high doses of DCI alone could worsen ovarian androgen imbalance. Most clinical protocols now use myo-inositol as the primary form, sometimes combined with DCI in a 40:1 ratio that mirrors the body’s natural balance.
How Long Before You Notice Changes
Most clinical trials measure outcomes at 12 weeks or 6 months. The 12-week mark is when studies consistently report improvements in LH, insulin, testosterone, and the LH-to-FSH ratio. One study of 20 overweight women with PCOS found restoration of menstrual and reproductive function after 12 weeks. A larger trial of 100 women tracked over six months confirmed regularization of menstrual cycles by that point.
If you’re taking inositol specifically to support progesterone through better ovulation, expect to give it at least three months. Follicle development takes roughly 90 days from early recruitment to ovulation, so improvements in the hormonal environment need that window to translate into a mature, ovulatory cycle.
Typical Dosage in Studies
The most commonly studied dose is 2 grams of myo-inositol twice daily (4 grams total), often paired with 200 to 400 micrograms of folic acid. Some trials used 1 gram twice daily and still observed significant hormonal improvements. The combination with folic acid appears in most protocols, partly because folic acid is standard for reproductive health and partly because it was included in the formulations studied.
Myo-inositol is generally well tolerated. It’s a naturally occurring sugar alcohol found in fruits, beans, and grains, and the body produces small amounts of it. At supplement doses, digestive side effects like bloating or loose stools can occur but tend to be mild.
Who Benefits Most
The strongest evidence for inositol raising progesterone applies to women with PCOS who aren’t ovulating regularly. If your low progesterone stems from anovulation driven by insulin resistance and excess androgens, inositol targets the root causes effectively. For women without PCOS whose low progesterone has a different origin, such as hypothalamic amenorrhea, thyroid dysfunction, or age-related decline in ovarian reserve, the evidence is much thinner. Inositol’s mechanism of action centers on insulin signaling and ovarian steroidogenesis pathways that are specifically disrupted in PCOS, which is why nearly all the clinical data comes from that population.